Notably, the mRNA expression of S100P was significantly increased in patients with stage II-IV compared to patients with stage I, suggesting that S100P may potentially contribute to the progression of pancreatic cancer (Figure S2). This evidence concerns the gene S100P and pancreatic neoplasm.